Loromisin
Brand names,
Loromisin
Analogs
Loromisin
Brand Names Mixture
Loromisin
Chemical_Formula
C11H12Cl2N2O5
Loromisin
RX_link
http://www.rxlist.com/cgi/generic3/chloramphenicol.htm
Loromisin
fda sheet
Loromisin
msds (material safety sheet)
Loromisin
Synthesis Reference
No information avaliable
Loromisin
Molecular Weight
323.129 g/mol
Loromisin
Melting Point
150.5 oC
Loromisin
H2O Solubility
2500 mg/L (at 25 °C)
Loromisin
State
Solid
Loromisin
LogP
1.476
Loromisin
Dosage Forms
Capsule; Drops; Liquid; Ointment; Powder; Solution; Suspension; Tablet
Loromisin
Indication
Used in treatment of cholera, as it destroys the vibrios and decreases the diarrhea. It is effective against tetracycline-resistant vibrios. It is also used in eye drops or ointment to treat bacterial conjunctivitis.
Loromisin
Pharmacology
Chloramphenicol is a broad-spectrum antibiotic that was derived from the bacterium Streptomyces venezuelae and is now produced synthetically. Chloramphenicol is effective against a wide variety of microorganisms, but due to serious side-effects (e.g., damage to the bone marrow, including aplastic anemia) in humans, it is usually reserved for the treatment of serious and life-threatening infections (e.g., typhoid fever). Chloramphenicol is bacteriostatic but may be bactericidal in high concentrations or when used against highly susceptible organisms. Chloramphenicol stops bacterial growth by binding to the bacterial ribosome (blocking peptidyl transferase) and inhibiting protein synthesis.
Loromisin
Absorption
Rapidly and completely absorbed from gastrointestinal tract following oral administration (bioavailability 80%). Well absorbed following intramuscular administration (bioavailability 70%). Intraocular and some systemic absorption also occurs after topical application to the eye.
Loromisin
side effects and Toxicity
Oral, mouse: LD50 = 1500 mg/kg; Oral, rat: LD50 = 2500 mg/kg. Toxic reactions including fatalities have occurred in the premature and newborn; the signs and symptoms associated with these reactions have been referred to as the gray syndrome. Symptoms include (in order of appearance) abdominal distension with or without emesis, progressive pallid cyanosis, vasomotor collapse frequently accompanied by irregular respiration, and death within a few hours of onset of these symptoms.
Loromisin
Patient Information
No information avaliable
Loromisin
Organisms Affected
Enteric bacteria and other eubacteria